Leukemias, lymphomas, and other hematologic cancers:
Indications for: Cladribine
Active hairy cell leukemia.
Give by continuous IV infusion for 7 consecutive days. 0.09mg/kg per day.
See full labeling.
Administer under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Risk of neurological toxicity. Acute nephrotoxicity has been observed with high doses (esp. when concomitant with other nephrotoxic treatments).
Delay or discontinue if neurotoxicity or renal toxicity occurs. Myelosuppression. Active infection. Renal or hepatic insufficiency. Monitor blood counts (esp. during first 4–8 weeks post-dose), renal and hepatic function. Pregnancy (Cat.D), nursing mothers: not recommended.
Chlorinated purine nucleoside analog.
Live attenuated vaccines: not recommended. Increased toxicity with myelosuppressive, immunosuppressive, or nephrotoxic agents.
Severe myelosuppression (eg, neutropenia, anemia, thrombocytopenia), fever, infection, fatigue, nausea, rash, headache, inj site reactions, others; neurotoxicity, nephrotoxicity, tumor lysis syndrome (rare).
Generic Drug Availability: